OnKure Therapeutics, Inc. (OKUR) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Boulder, CO, 미국. 현재 CEO는 Nicholas A. Saccomano.
OKUR 을(를) 보유 IPO 날짜 2021-04-08, 46 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $62.97M.
OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.
